Mark Soberman becomes president of ACCC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Mark Soberman, was elected as the 2017-2018 President of the Association of Community Cancer Centers during its annual meeting March 31.

A thoracic surgeon and thoracic oncologist, Soberman is the medical director, Oncology Service Line and chief physician executive, Monocacy Health Partners at Frederick Regional Health System.

Soberman has been an active member of ACCC, serving on the executive committee of the board of trustees and as President-Elect (2016-2017).

He is a reviewer for the Annals of Thoracic Surgery and an active member of numerous organizations, including the Society of Thoracic Surgeons, the Southern Thoracic Surgical Association, the General Thoracic Surgical Club, the American Association for Physician Leadership, the American College of Healthcare Executives, and the American Society of Clinical Oncology.

Previously, Soberman served as vice-chair of the Department of Surgery; director, Section of Thoracic Oncology; and director, Section of Thoracic Surgery at MedStar Washington Hospital Center. Soberman has held leadership positions as Director, Division of Thoracic S urgery at Georgetown University Hospital, and Director, Section of Thoracic Surgery at Sibley Memorial Hospital.

His academic appointments include clinical associate professor of surgery at Georgetown University School of Medicine and Clinical Assistant Professor of Surgery at George Washington University School of Medicine.

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login